Allarity Therapeutics Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
ALLR
- Investments
-
3
- Share Price
-
$0.90
- (As of Wednesday Closing)
Allarity Therapeutics General Information
Description
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Contact Information
Website
www.allarity.comCorporate Office
- East Tarpon Avenue
- 123
- Tarpon Springs, FL 34689
- United States
Corporate Office
- East Tarpon Avenue
- 123
- Tarpon Springs, FL 34689
- United States
Allarity Therapeutics Stock Performance
As of 18-Nov-2026, Allarity Therapeutics’s stock price is $0.90. Its current market cap is $14.3M with 16M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.90 | $0.84 | $0.77 - $1.84 | $14.3M | 16M | 128K | -$0.79 |
Allarity Therapeutics Financials Summary
As of 30-Jun-2026, Allarity Therapeutics has a trailing 12-month revenue of $345K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 22,209 | 1,837 | (11,939) | 4,754 |
| Revenue | 345 | 320 | 0 | 0 |
| EBITDA | (11,992) | (11,847) | (24,767) | (11,305) |
| Net Income | (12,334) | (11,231) | (24,515) | (11,901) |
| Total Assets | 32,115 | 18,258 | 22,650 | 11,862 |
| Total Debt | 22,286 | 1,400 | 1,350 | 1,300 |
Allarity Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Allarity Therapeutics Comparisons
Industry
Financing
Details
Allarity Therapeutics Competitors (12)
One of Allarity Therapeutics’s 12 competitors is Kura Oncology, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kura Oncology | Formerly VC-backed | San Diego, CA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Prelude Therapeutics | Formerly VC-backed | Wilmington, DE | ||||
| Lantern Pharma | Formerly VC-backed | Dallas, TX |
Allarity Therapeutics Patents
Allarity Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2026201368-A1 | Methods for predicting responsiveness to daratumumab in a cancer subject | Pending | 20-Mar-2025 | ||
| EP-4837974-A2 | Methods for predicting responsiveness to daratumumab in a cancer subject | Pending | 20-Mar-2025 | ||
| US-20260286445-A1 | Methods for predicting responsiveness to daratumumab in a cancer subject | Pending | 20-Mar-2025 | ||
| US-20240325396-A1 | Methods for treating cancer | Pending | 17-Mar-2023 | ||
| WO-2016046640-A2 | Methods for predicting drug responsiveness | Inactive | 26-Sep-2014 | C12Q1/6886 |
Allarity Therapeutics Signals
Allarity Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Allarity Therapeutics Investments & Acquisitions (3)
Allarity Therapeutics’s most recent deal was a Merger/Acquisition with Oncology Venture US for . The deal was made on 13-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oncology Venture US | 13-Jul-2020 | Merger/Acquisition | Drug Discovery | ||
| Sass & Larsen (Dovitinib Program Based in Boston, Massachusetts) | 08-Jun-2020 | Corporate Asset Purchase | Pharmaceuticals | ||
| Oncology Venture Sweden | 24-Aug-2018 | Merger/Acquisition | Drug Discovery |
Allarity Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Allarity Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Oncology Venture Sweden | Horsholm, Denmark | 2012 |
Allarity Therapeutics FAQs
-
When was Allarity Therapeutics founded?
Allarity Therapeutics was founded in 2004.
-
Where is Allarity Therapeutics headquartered?
Allarity Therapeutics is headquartered in Tarpon Springs, FL.
-
What is the size of Allarity Therapeutics?
Allarity Therapeutics has 8 total employees.
-
What industry is Allarity Therapeutics in?
Allarity Therapeutics’s primary industry is Drug Discovery.
-
Is Allarity Therapeutics a private or public company?
Allarity Therapeutics is a Public company.
-
What is Allarity Therapeutics’s stock symbol?
The ticker symbol for Allarity Therapeutics is ALLR.
-
What is the current stock price of Allarity Therapeutics?
As of 18-Nov-2026 the stock price of Allarity Therapeutics is $0.90.
-
What is the current market cap of Allarity Therapeutics?
The current market capitalization of Allarity Therapeutics is $14.3M.
-
What is Allarity Therapeutics’s current revenue?
The trailing twelve month revenue for Allarity Therapeutics is $345K.
-
Who are Allarity Therapeutics’s competitors?
Kura Oncology, Bristol-Myers Squibb, Sutro Biopharma, Prelude Therapeutics, and Lantern Pharma are some of the 12 competitors of Allarity Therapeutics.
-
What is Allarity Therapeutics’s annual earnings per share (EPS)?
Allarity Therapeutics’s EPS for 12 months was -$0.79.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process